|Guidelines for the use and interpretation of assays for monitoring autophagy|
DJ Klionsky, K Abdelmohsen, A Abe, MJ Abedin, H Abeliovich, ...
Autophagy 12 (1), 1-222, 2016
|VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex|
KV Lu, JP Chang, CA Parachoniak, MM Pandika, MK Aghi, D Meyronet, ...
Cancer cell 22 (1), 21-35, 2012
|Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma|
YL Hu, M DeLay, A Jahangiri, AM Molinaro, SD Rose, WS Carbonell, ...
Cancer research 72 (7), 1773-1783, 2012
|Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation|
MK Aghi, BS Carter, GR Cosgrove, RG Ojemann, S Amin-Hanjani, ...
Neurosurgery 64 (1), 56-60, 2009
|Oncolytic viral therapies–the clinical experience|
M Aghi, RL Martuza
Oncogene 24 (52), 7802-7816, 2005
|Impact of extent of resection for recurrent glioblastoma on overall survival|
O Bloch, SJ Han, S Cha, MZ Sun, MK Aghi, MW McDermott, MS Berger, ...
Journal of neurosurgery 117 (6), 1032-1038, 2012
|Human glioblastoma–derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors|
H Wakimoto, S Kesari, CJ Farrell, WT Curry, C Zaupa, M Aghi, T Kuroda, ...
Cancer research 69 (8), 3472-3481, 2009
|Prodrug activation enzymes in cancer gene therapy|
M Aghi, F Hochberg, XO Breakefield
The journal of gene medicine 2 (3), 148-164, 2000
|Biology of angiogenesis and invasion in glioma|
MC Tate, MK Aghi
Neurotherapeutics 6 (3), 447-457, 2009
|Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes|
M Aghi, KS Cohen, RJ Klein, DT Scadden, EA Chiocca
Cancer research 66 (18), 9054-9064, 2006
|Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group|
MA Vogelbaum, S Jost, MK Aghi, AB Heimberger, JH Sampson, PY Wen, ...
Neurosurgery 70 (1), 234-244, 2012
|Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy|
CM Kramm, M Chase, U Herrlinger, A Jacobs, PA Pechan, NG Rainov, ...
Human gene therapy 8 (17), 2057-2068, 1997
|Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies|
M Aghi, TC Cho, EA Chiocca, CM Kramm, XO Breakefield
JNCI: Journal of the National Cancer Institute 90 (5), 370-380, 1998
|Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine …|
M Aghi, TC Chou, K Suling, XO Breakefield, EA Chiocca
Cancer research 59 (16), 3861-3865, 1999
|Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance|
A Jahangiri, M De Lay, LM Miller, WS Carbonell, YL Hu, K Lu, MW Tom, ...
Clinical Cancer Research 19 (7), 1773-1783, 2013
|Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy|
YL Hu, A Jahangiri, M DeLay, MK Aghi
Cancer research 72 (17), 4294-4299, 2012
|Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication|
M Aghi, S Rabkin, RL Martuza
Journal of the National Cancer Institute 98 (1), 38-50, 2006
|Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging|
RF Barajas Jr, JJ Phillips, R Parvataneni, A Molinaro, E Essock-Burns, ...
Neuro-oncology 14 (7), 942-954, 2012
|Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial|
O Bloch, CA Crane, Y Fuks, R Kaur, MK Aghi, MS Berger, NA Butowski, ...
Neuro-oncology 16 (2), 274-279, 2014
|New advances that enable identification of glioblastoma recurrence|
I Yang, MK Aghi
Nature Reviews Clinical Oncology 6 (11), 648, 2009